Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOX-SL in AIDS-Related Kaposi's Sarcoma
NCT00002319Phase 3Completed
- Sponsor
- Sequus Pharmaceuticals, Inc.
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegylated liposomal doxorubicin in Kaposi sarcoma (KS), sponsored by Sequus Pharmaceuticals, Inc. Primary endpoints: Evaluation of KS lesions and Safety Evaluation. Status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT00002319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002319.